Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$2.66 USD
-0.09 (-3.27%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $2.66 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ESPR 2.66 -0.09(-3.27%)
Will ESPR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ESPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ESPR
Are Options Traders Betting on a Big Move in Esperion Therapeutics Stock?
ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises
ESPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates
Other News for ESPR
ESPR's price falls by 3.27% on September 20, though its technical setup remains stable.
Esperion’s Strategic Milestone: Nexletol Approval in Japan Boosts Financial Outlook with $120 Million Potential
ESPR: HC Wainwright & Co. Reiterates Buy Rating with $16 Target | ESPR Stock News
Esperion’s Strategic Advancements: Regulatory Approval and Market Expansion Boost
NEXLETOL Approval in Japan Boosts Esperion (ESPR) Prospects